BioSpace News Archive

Keratosis Pilaris is a non-contagious skin disorder that causes the outermost layers of skin to thicken, especially on the upper arms and thighs, buttocks, and on the face

The veterinary orthopedic implant market expects to churn good growth during the forecast period of 2018-2026 due to the rising demand for effective animal care.

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome due to COVID-19 infection.

ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting. A webcast of the pr

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infantile) and Type II (late inf

Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of A

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older. “With no currently approved therapies outside the United States to treat hemolytic anemia in sickle cell disease, the unmet need in this devastating di

- Call will take place on Friday, December 11, 2020 at 11:00 AM ET TORONTO and HOUSTON, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a key opinion leader (KOL) call on MDNA55 for the treatment of recurrent glioblastoma multiforme (rGBM) on Friday, December 11, 2020 at 11:00 AM ET.

Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and